Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children’s hospitals in the United States. Clin Infect Dis. 2009;49:65–71. [PMC free article: PMC2897056] [PubMed: 19463065]

Herigon JC, Hersh AL, Gerber JS, Zaoutis TE, Newland JG. Antibiotic management of Staphylococcus aureus infections in US children’s hospitals, 1998-2008. Pediatrics. 2010;125:e1294–300. [PubMed: 20478934]

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012;307:483–90. [PMC free article: PMC6362452] [PubMed: 22253364]

Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc. 1999;74:825–833. [PubMed: 10473362]

Clindamycin Injection [Package Insert]. Schaumberg, IL: APP Pharmaceuticals; 2008.

Manjunath PP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27:1081–1091. [PubMed: 17655508]

Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients. Clin Pharmacokinet. 2000;38:415–426. [PubMed: 10843460]

Falagas ME, Kompoti M. Obesity and Infection. Lancet Infect Dis. 2006;6:438–446. [PubMed: 16790384]

Reed MD. Reversing the Myths Obstructing the Determination of Optimal Age- and Disease-Based Dosing in Pediatrics. J Pedatr Pharmacol Ther. 2011;16:4–13. [PMC free article: PMC3136233] [PubMed: 22477819]

Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis. 2003;7:513–520. [PubMed: 12839703]

Bradley JS, Garonzik SM, Forrest AF, Bhavnani SM. Selecting the best antimicrobial dose totreat an infection. Ped Infect Dis J. 2010;29:1043–1046. [PubMed: 20975453]

Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE,Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther. 2014;96(4):429–37. [PMC free article: PMC4169790] [PubMed: 24949994]

Bell MJ, Shackelford P, Smith RS, Schroeder K. Pharmacokinetics of clindamycin phosphatein the first year of life. J Pediatr. 1984;9:482–486. [PubMed: 6470871]

Koren G, Zarlin Y, Maresky D, Spiro TE, MacLeod SM. Pharmacokinetics of intravenousclindamycin in newborn infants. Ped Pharmacol. 1986;5:287–292. [PubMed: 3737273]

DeHann RM, Schellenberg D. Clindamycin palmitate flavored granules. Multidose tolerance, absorption, and urinary excretion study in healthy children. J Clin Pharmacol. 1972;74–83. [PubMed: 4480976]

DeHaan RM, Metzler CM, Schellenberg D, Vandenbosch WD. Pharmacokinetic Studies ofclindamycin phosphate. J Clin Pharmacol. 1973;13:190–209. [PubMed: 4488654]

Carrasco-Portugal MdC, Lujan M, Flores-Murrieta FJ. Evaluation of gender in the oralpharmacokinetics of clindamycin in humans. Biopharm Drug Dispos.. 2008;29:427–430. [PubMed: 18623043]

DeHaan, RM, Metzler CM, Schellenberg D, VandenBosch WD, Masson EL. Pharmacokinetic studies of clindamycin hydrochloride in humans. Int J Clin Pharmacol Ther Toxicol. 1972;6:105–119. [PubMed: 4638969]

Townsend RJ, Baker RP. Pharmacokinectic comparison of three clindamycin phosphatedosing schedules. Drug Intell Clinical Pharm. 1987;3:279–281. [PubMed: 3569028]

Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. In Vitro metabolism ofclindamycin in human liver and intestinal microsomes. Drug Metab Dispo. 2003;31:878–887. [PubMed: 12814964]

Green B, Duffull SB. Caution when lean body weight is used as a size descriptor for obesesubjects. Clin Pharm Ther. 2002;72:743–744. [PubMed: 12496756]

Erstad BL. Which Weight for Weight-Based Dosage Regimens in Obese Patients? Am J Health Syst Pharm. 2002;59:2105–2110. [PubMed: 12434728]

Weiss M. How does obesity affect residence time dispersion and the shape of drugdisposition curves? Thiopental as an example. J Pharmacokinet Pharmacodyn. 2008;35:325–336. [PubMed: 18465214]

Berezhkovskiy LM. On the accuracy of estimation of basic pharmacokinetic parameters bythe traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci. 2011;100:2482–2497. [PubMed: 21254063]

Morrish GA, Manjunath PP, Green B. The effects of obesity on drug pharmacokinetics inhumans. Expert Opin Drug Metab Toxicol. 2011;7:697–706. [PubMed: 21417960]

Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Practice Res Clin Anaesth. 2010;25:27–36. [PubMed: 21516911]

Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin interm pregnancy. Am J Obstet Gynecol. 1976;124:688–691. [PubMed: 943947]

Reeves DS, Holt HA, Phillips I, King A, Miles RS, Paton R, Wise R, Andrews JM. Activityof clindamycin against Staphylococcus aureus and Staphylococcus epidermidis from four UK centres. J. Antimicrob. Chemother. 1991;27:469–474. [PubMed: 1856126]

Gatti G, Flaherty J, Bubp J. Comparative study of bioavailabilities and pharmacokinetics ofclindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993;37(5):1137–43. [PMC free article: PMC187917] [PubMed: 8517703]